Patients receiving SGLT2 inhibitors were more likely to have high levels of hyperlipidemia and obesity and to be simultaneously receiving GLP-1 agonists, insulin, metformin, and statins compared with those receiving DPP4 inhibitors. This evidence concerns the gene DPP4 and hyperlipidemia.